Thalidomide and analogs

Erin R. Gardner, Giuseppe Di Lorenzo, William D. Figg*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

1 Scopus citations


Thalidomide (Thalomid®), originally marketed as a sedative in Europe in the 1950s but withdrawn after teratogenicity was observed, has experienced a resurgence of interest due to its apparent anti-angiogenic and immunomodulatory properties. Thalidomide is currently in clinical testing for the treatment of prostate cancer. Numerous studies that have been completed, or are currently ongoing, have demonstrated promising activity. Thalidomide has been tested as a single agent and in combination with both targeted agents, such as bevacizumab, and traditional cytotoxic drugs, such as paclitaxel and docetaxel, in the majority of the studies. A range of thalidomide analogs have been generated in an effort to improve the clinical activity while reducing the side effect profile. Lenalidomide (Revlimid), an immunomodulatory analog of thalidomide, has entered clinical trials in prostate cancer and is being tested in many of the same combinations. This chapter reviews the clinical trials of thalidomide and lenalidomide initiated or completed to date, including dosing, clinical response, and toxicity.

Original languageEnglish
Title of host publicationDrug Management of Prostate Cancer
PublisherSpringer New York
Number of pages9
ISBN (Print)9781603278317
StatePublished - 2010
Externally publishedYes


  • Angiogenesis
  • Immunomodulatory
  • Lenalidomide
  • Prostate cancer
  • Thalidomide


Dive into the research topics of 'Thalidomide and analogs'. Together they form a unique fingerprint.

Cite this